

About RF
Rheumatoid factor (RF) is an autoantibody linked to chronic inflammation in RA3,4
RF
RF neutralizes IgG by binding to the Fc domain3
Fc, fragment crystallizable; IgG1, immunoglobulin G1.
Prevalence of RF
The majority of RA patients are positive for RF and present with varying levels3
Prevalence of RF
Disease burden in high RF
RA patients with higher RF levels are at risk of experiencing a more aggressive and destructive form of RA3-5
Patients with higher RF levels are more likely to experience5-8:
High RF should be considered when making treatment decisions.5
Higher RF levels may be associated with lower drug concentrations in certain biologic therapies.3,9,10
Peer perspectives on the impact of high RF levels
Drs. Erin L. Arnold and Soha Dolatabadi discuss the importance of considering RF levels when diagnosing and
treating RA
The Central Role of Rheumatoid Factor in the Pathophysiology of Rheumatoid Arthritis
High Levels of Rheumatoid Factor as a Prognostic Indicator in Rheumatoid Arthritis
CIMplicity can help provide ongoing support for your patients throughout their journey.
Interested in CIMZIA
In-Office Injection?
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member.
CIMZIA is a tumor necrosis factor (TNF) blocker indicated for:
CONTRAINDICATIONS
CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.
SERIOUS INFECTIONS
Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue CIMZIA if a patient develops a serious infection or sepsis.
Reported infections include:
Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member.
HEART FAILURE
HYPERSENSITIVITY
HEPATITIS B VIRUS REACTIVATION
NEUROLOGIC REACTIONS
HEMATOLOGIC REACTIONS
DRUG INTERACTIONS
AUTOIMMUNITY
IMMUNIZATIONS
ADVERSE REACTIONS
Please refer to full Prescribing Information.
US-CZ-2400612
References: 1. CIMZIA® [prescribing information]. Smyrna, GA: UCB, Inc. 2. Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-3329. 3. Tanaka Y, Takeuchi T, Haaland D, et al. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: post-hoc analysis of clinical trials. Int J Rheum Dis. 2023;26(7):1248-1259. 4. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727-734. 5. Nell VPK, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64(12):1731-1736. 6. Fazeli MS, Khaychuk V, Wittstock K, et al. Cardiovascular disease in rheumatoid arthritis: risk factors, autoantibodies, and the effect of antirheumatic therapies. Clin Med Insights Arthritis Musculoskelet Disord. 2021;14:11795441211028751. doi:10.1177/1179541211028751 7. Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69(9):1649-1654. 8. England BR, Sayles H, Michaud K, et al. Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):36-45. 9. Martinez-Feito A, et al. Does TNF inhibitor molecular structure matter? Analysis of impact of baseline rheumatoid factor titers on drug levels in patients with rheumatoid arthritis. Abstract presented at: EULAR 2022 Annual Meeting; June 1-4, 2022; Copenhagen, Denmark. 10. Nakayama Y, Watanabe R, Murakami K, et al. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatol Int. 2022;42(7):1227-1234.